472 results on '"Kuball, Jürgen"'
Search Results
2. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
3. CRISPR screens decode cancer cell pathways that trigger γδ T cell detection.
4. Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion (DLI) 2.0
5. Clinical and Biological Concepts for Mastering Immune Reconstitution After Hematopoietic Cell Transplantation: Toward Practical Guidelines and Greater Harmonization
6. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
7. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
8. CRISPR screens decode cancer cell pathways that trigger γδ T cell detection
9. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
10. Graft engineering: how long can you wait, how low can you go, and pandemic readiness
11. Uncovering the mode of action of engineered T cells in patient cancer organoids
12. GoCART
13. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
14. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
15. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
16. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
17. Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients
18. Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
19. Reactivation of Multidrug-Resistant HSV-1 in a Post–Allogenic Hematopoietic Stem Cell Transplant Patient: Dynamic Detection of the Rare A605V Mutation by Next-Generation Sequencing.
20. Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT
21. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT
22. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data
23. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
24. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
25. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
26. αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies
27. Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study
28. Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion
29. Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization
30. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile
31. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
32. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study
33. Basics of Advanced Therapy Medicinal Product Development in Academic Pharma and The Role of a GMP Simulation Unit
34. Correction to: Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients
35. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status
36. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT
37. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
38. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
39. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
40. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.
41. Tyrosine kinase inhibitor levels matter in treating chronic GVHD
42. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
43. Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib
44. Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP
45. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report
46. Supplementary Table 1-4, Supplementary Figures 1-3 from An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia
47. Supplementary Figures 1-3 from Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
48. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
49. Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion
50. Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.